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Cristina Di Carluccio,1,6 Rosa Ester Forgione,1,6 Marco Montefiori,2 Monica Civera,2 Sara Sattin,2
Giovanni Smaldone,3 K. Fukase,4 Y. Manabe,4 Paul R. Crocker,5 Antonio Molinaro,1 Roberta Marchetti,1,7,*
and Alba Silipo1,*SUMMARY
Siglecs (sialic acid binding immunoglobulin (Ig)-like lectins) constitute a group of
15 human and 9 murine cell-surface transmembrane receptors belonging to the I-
type lectin family, mostly expressed on innate immune cells and characterized by
broadly similar structural features. Here, the prominent inhibitory CD22 (Siglec-
2), well known in maintaining tolerance and preventing autoimmune responses
on B cells, is studied in its human and murine forms in complex with sialoglycans.
In detail, the role of the N-glycolyl neuraminic acid (Neu5Gc) moiety in the inter-
action with both orthologueswas explored. The analysis of the bindingmodewas
carried out by the combination of NMR spectroscopy, computational approaches,
and CORCEMA-ST calculations. Our findings provide a first model of Neu5Gc
recognition by h-CD22 and show a comparable molecular recognition profile by
h- and m-CD22. These data open the way to innovative diagnostic and/or thera-
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Sialic acids (Sias) comprise a family of nearly 50 members of acidic monosaccharides, expressed by species
belonging to the vertebrates and characterized by a particular nine-carbon sugar backbone. The two pre-
dominant forms of sialic acid in mammals are the N-acetyl neuraminic acid (Neu5Ac) and the N-glycolyl
neuraminic acid (Neu5Gc). The latter is biosynthesized by the enzymatic addition of a hydroxyl group to
N-acetyl moiety at 50-position of Neu5Ac, catalyzed by a hydroxylase/monooxygenase enzyme, the cyti-
dine monophospho-N-acetyl neuraminic acid hydroxylase (CMAH). However, in contrast to mouse or great
apes such as chimpanzee, in humans the specific loss of Neu5Gc expression is ascribed to a fixed genomic
mutation in CMAH that leads to the gene loss in the hominin lineage (Okerblom and Varki, 2017). Despite
the inability to produce Neu5Gc, it can be exogenously introduced from specific dietary sources, such as
red meat and cow’s milk, and metabolized via the Neu5Ac biochemical pathway (Okerblom and Varki,
2017; Varki, 2017). Different studies reported the presence of Neu5Gc on fetal tissues and on tumor cells,
such as melanoma, retinoblastoma, colon cancer, and breast cancer (Samraj et al., 2014). Low levels of
Neu5Gc were also detected on the surfaces of human secretory epithelia and small- and large-blood ves-
sels endothelia (Varki, 2017). Therefore, Neu5Gc can be considered a pioneering example of ‘‘xeno-auto-
antigen.’’ The anti-Neu5Gc antibodies detected in humans contribute to establish ‘‘xenosialitis,’’ a chronic
inflammation state in Neu5Gc-enriched tissues that can significantly impact cancer progression, increasing
tumor-associated inflammation (Altman and Gagneux, 2019; Zhou et al., 2020).
Sias are considered self-associated molecular patterns (SAMPs), as they function as determinant of ‘‘self’’
through their intrinsic recognition by specific inhibitory receptors belonging to the Siglec family (Häubli
and Varki, 2020; Duan and Paulson, 2020). These receptors assist immune cells in the discrimination be-
tween ‘‘self’’ and ‘‘non-self’’ and constitute important regulators of the immune system (Macauley et al.,
2014). Their functions depend on their unique and precise sialoglycans’ binding specificity as well as on
their expression pattern within different cellular compartments (Di Carluccio et al., 2021). Siglecs represent
a family of immune proteins that can be classified in two different and evolutionary conserved sub-groups;
one comprises Sialoadhesin (Siglec-1), CD22 (Siglec-2), MAG (Siglec-4) and Siglec-15, whereas the otheriScience 24, 101998, January 22, 2021 ª 2020 The Author(s).





Articleincludes the so-called CD33 (Siglec-3)-related family, rapidly evolving and displaying high homology with
the precursor, namely Siglec-3. Despite this differentiation, Siglecs share the ability to recognize and bind
to sialic acid epitopes through the N-terminal V (variable)-set domain. Siglecs also possess a variable num-
ber (from 1 to 16) of ‘‘C2-set’’ Ig-like domains followed by a single pass trans-membrane region; most of
Siglecs feature cytoplasmic tyrosine motifs, such as ITIM (immunoreceptor tyrosine-based inhibitory motif)
and ITIM-like regions, which confer inhibitory signaling properties. A few activatory-type Siglecs, such as
Siglecs-14–16, contain instead a positively charged amino acid in their transmembrane region and asso-
ciate with immunoreceptor tyrosine-based activatory motif (ITAM)-containing adaptor proteins (Ajit and
Angata, 2006).
The sialic acids are diversely recognized among the Siglec family, for example MAG only binds to Neu5Ac,
human and murine sialoadhesin show a strong preference for Neu5Ac over Neu5Gc, whereas murine and
human CD22 bind both, with m-CD22 preferring Neu5Gc over Neu5Ac (Angata, 2018). Interestingly, major
human pathogens have evolved the ability to mimic Neu5Ac-containing structures, either synthesized de
novo or scavenged from the host, to escape immune surveillance. In contrast, only a few pathogens express
Neu5Gc or Neu5Gc-like structures (Varki, 2017).
Within this context, we here considered an interesting Siglec member, the inhibitory CD22 (h-Siglec-2
and its murine ortholog m- Siglec-2), expressed on the surface of B cells and to a lesser extent of
T cells, able to modulate B cell tolerance by counteracting B cell receptor (BCR) signaling. On resting
B-cells, CD22 is ‘‘masked’’ by cis interactions with sialoglycans exposed on the same plasma membrane,
resulting in the formation of CD22 homo-oligomers (Han et al., 2005). Conversely, upon BCR activation,
CD22 clusters are recruited to the BCR and, together with Siglec-10, negatively regulate the B cell
signaling. CD22 malfunctioning and the resulting lack of appropriate BCR inhibition has been linked
to several B-cell-related pathologies, such as hairy cell leukemia, marginal zone lymphoma, chronic lym-
phocytic leukemia, and non-Hodgkin lymphoma (Müller and Nitschke, 2014; Mahajan and Pillai, 2016;
Dörner et al., 2012).
Because Siglecs, and indeed CD22, are considered effective glyco-immuno checkpoints within cancer
immunotherapy (Duan and Paulson, 2020), and because changes in the Neu5Gc/Neu5Ac ratio can poten-
tially modulate Siglecs’ binding and signaling properties, understanding the basis of Neu5Gc - Siglec inter-
action may have therapeutic implications. Thus, also considering that the molecular details of Neu5Gc
recognition by Siglecs are still far from being explored in-depth, we here aimed to understand the differ-
ences in the ability of human and murine CD22 to recognize and bind to various sialoglycans. To achieve
this aim, we elucidated the molecular mechanisms of Neu5Gc recognition by, and binding to, human
CD22/Siglec-2 (h-CD22) and compared it with the murine ortholog m-Siglec-2 (m-CD22). We combined
NMR spectroscopy to computational approaches such as Molecular Dynamics, docking, and COR-
CEMA-ST methods, thus collecting pivotal information concerning the binding epitope and the conforma-
tional behavior of Neu5Gc containing glycans.RESULTS
The interaction between different sialoglycans bearing acetylated or glycolylated sialic acid, namely
Neu5Ac and Neu5Gc with human and murine CD22, was investigated as follows.Binding specificity of m- and h- CD22 toward Neu5Ac and Neu5Gc ligands
The binding affinities of both m-CD22 and h-CD22 toward Neu5Gc- and Neu5Ac-containing ligands were
evaluated by fluorescence analyses; in detail, fluorescence titrations of increasing amounts of sialoglycans
into a fixed concentration of the proteins were performed. The results demonstrated the ability of m- and h-
CD22 to similarly recognize acetylated and glycolylated sialoglycans (Figure 1), as supported by the
derived values of binding constants (Kb), all in the micromolar range. Thus, human andmurine CD22 recog-
nized the examined sialoconjugates comparably.Glycolylated 6’SLN displays a comparablemolecular behavior in the binding pocket of murine
and human CD22
The glycolylated 6’-sialylactosamine [Neu5Gc-a-(2,6)-Gal-b-(1,4)-GlcNAc-b-OR, 60SLN] was investigated
upon binding to human and murine CD22. A detailed STD NMR (Meyer and Peters, 2003; Angulo and2 iScience 24, 101998, January 22, 2021
Figure 1. Fluorescence titrations
Fluorescence spectra of m-CD22 (upper panel, black lines) or hCD22 (lower panel, black lines) in the presence of
increasing amounts of Neu5Gc-containing ligand (colored lines) or Neu5Ac-containing ligand (colored lines),
respectively. The binding isotherm and the values of the binding constants (Kb) are also reported. For each data point,
10% Y error bars are shown.
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Figure 2. STD NMR analysis of glycolylated and acetylated Sia-a-(2,6)-Gal-b-(1,4)-GlcNAc-bOCH2CH2NH2
interacting with murine and human CD22
(A) Reference 1H NMR spectrum (black) and STD 1D NMR spectrum (red) with a molecular ratio m-CD22/glycolylated
ligand of 1:100 at saturation time of 2s. On the right, STD build-up curves are reported. STD build-up curves are calculated
using the following monoexponential equation: STD ðtsatÞ = STDmaxð1  eksat tsat Þ, where STD (tsat) is the STD signal
intensity of each proton at tsat saturation time, STD
max is the asymptotic maximum of the curve and ksat represents the
observed saturation rate constant measuring the speed of STD build-up. The highest STD signal intensity is referred to
the glycolyl/acetyl group of sialic acid, set to 100%, whereas the other protons were normalized to this value. The STD-
derived epitope mapping on the molecular envelope of Neu5Gc ligand in the bioactive conformation with color code
according to the observed STD effects is also shown.
(B)On the left, epitopemapof theglycolylated ligand interactingwith h-CD22, calculated from the ratio (I0Isat)/I0, where (I0Isat)
is the STD signal and I0 is the peak intensity of the unsaturated reference spectrum. STDeffects lower than 10% are not indicated.
In themiddle, the STD-derived epitopemapping on themolecular envelope of the ligand in its bioactive conformation is shown.
On the right, STD build up curves are reported.(C) On the left, epitopemap of the acetylated ligand interacting with m/h-CD22,
calculated from the ratio (I0Isat)/I0, where (I0Isat) is the STD signal and I0 is the peak intensity of the unsaturated reference
spectrum. STD effects lower than 10% are not indicated. In the middle, the STD-derived epitope mapping on the molecular
envelope of the ligand in its bioactive conformation is shown.On the right, STDbuild up curves are reported.H6R, H6S, H9R, and




ArticleNieto, 2011) analysis allowed us to map the epitopes of the ligand when interacting to both m-CD22 (Fig-
ure 2A) and h-CD22 (Figure 2B). The glycolylated ligand was recognized similarly by both receptors, as




Articlebelonged to the glycolyl moiety of Neu5Gc, whose signal was set to 100%. The sialic acid—galactose moi-
ety was the main determinant of the binding to both h-CD22 and m-CD22; in detail, H-7 of Neu5Gc (K7,
Figure 2A) was saturated more than 50%, whereas H-5, H-6, and H-8 of Neu5Gc (K5, K6 and K8 protons
in Figure 2A), as well as H-5 and H-4 of Gal (B5 and B4, Figure 2A) were in the range of 40%–50%. Further-
more, the STD signals of the diastereotopic H-3eq and H-3ax protons (K3) showed the lowest effects with
both murine and human CD22. The GlcNAc residue (A) was completely excluded from the CD22-binding
pocket (Figures 2A and 2B), indicating its solvent exposure. The construction of STD build-up curves (Yan
et al., 2003) then allowed to accurately define the glycolylated trisaccharide epitope excluding potential
artifacts caused by differences in the longitudinal relaxation time T1 of the ligand protons (Marchetti
et al., 2016) (Figures 2A and 2B, Tables S1 and S2).
The topology and conformation adopted by 60SLN when interacting with h- and m-CD22 (the bioactive confor-
mation)was achieved by transferredNOESY (tr-NOESY) analyses (Meyer and Peters, 2003). The stability of4 and
c dihedral angles of the glycosidic linkages in the free state was monitored during 100 ns Molecular Dynamic
simulation in explicit solvent, carried out using the Amber18 package (Case et al., 2018) (See also Methods
and Figure S2). Differently from the Neu5Ac trisaccharide (Di Carluccio et al., 2019; Forgione et al., 2020), that
in solution explores different populations depending on the values of 4 torsion angle (60/180), the Neu5Gc
glycan preferentially adopts a conformation with 4 around 60 (see Table S3).
As for the bound state, tr-NOESY analyses confirmed the preference of the glycolylated glycan for the en-
ergetic minimum characterized by 4/c dihedral angles of 60/180. The absence of NOE contacts be-
tween the H6-proR of galactose and the diastereotopic (axial and equatorial) H-3 protons of sialic acid
and the key NOE established between the acetyl group of GlcNAc and H-5 of sialic acid (Table S3)
observed in the tr-NOESY spectra (Figures S1B and S1C) revealed a bent conformation of the ligand, which
assumed a shape characterized by an umbrella-like topology when bound either to h-CD22 and m-CD22
(Chandrasekaran et al., 2008).Molecular modeling showed similar binding features of murine and human CD22 in the
interaction with glycolylated ligands
Computational studies including homology modeling, docking, and MD simulations were carried out to
describe the binding of CD22 with Neu5Gc ligands. The crystal structure of h-CD22 (PDB: 5VKJ) (Ereño-
Orbea et al., 2017) was used as structural template to model m-CD22, whose three-dimensional structure
is not available. The sequence encoding for m-CD22 extracellular V-set and C2-set domains was aligned
to the template sequence using BLAST (Basic Local Alignment Search Tool) (Altschul et al., 1990). Ac-
cording to the sequence alignment displayed in Figure 3A, m-CD22 expectedly showed significant
sequence identity (above 58%) relatively to h-CD22, in agreement with the conserved nature of CD22.
The target template alignment was submitted to the SWISS-MODEL (Waterhouse et al., 2018) server
to obtain a three-dimensional model of m-CD22; the structure quality was assessed through PROCHECK
web server (Laskowski et al., 1993), giving a Ramachandran plot in which 80.3% of model torsional angles
were in the mostly favored region and 19.4% in the additional allowed region. The m-CD22 structural
model obtained showed the typical Siglec Ig-like folding, with the sialic acid binding site located at
the summit of the N-terminal V-set domain (Figure 3B). Similarly to other Siglecs, m-CD22 binding site
architecture features a shallow pocket constituted by the A, F, and G strands and bound by the CC0
and GG0 variable loops. Compared with h-CD22, the composition of the binding site residues entitled
to sialylated epitopes binding was overall conserved. The most relevant differences lied in the replace-
ment of Lys23h, Tyr64h, and Lys127h with Asp25m, Phe68m, and Arg131m, which slightly affected the po-
larity of the binding region. Prior to docking calculations, the structural model was subjected to MD
simulation, monitoring along the trajectory the backbone RMSD and the RMSF of the whole structure,
as well as the RMSD of the CC0 and GG0 loops (Figures S3A–S3D). The analysis of the potential energy
along the simulation allowed to establish the m-CD22 structure at lowest energy, which was subse-
quently employed for docking calculations (Figure S3D).
To analyze its binding mode, the Neu5Gc ligand was docked into h-CD22- and m-CD22-binding sites by
means of Autodock 4.20 (Morris e al., 2009). The energies and populations of the top clusters were very
similar for both receptors, ranging from3.5 to2 kcal mol1 (Table S4). Thus, from analysis of the docking
results, the h-CD22/and m-CD22/ligand complexes displaying lower relative energy and higher cluster
populations were selected to run MD simulations. Notably, in the aforementioned poses Neu5Gc ligandiScience 24, 101998, January 22, 2021 5
Figure 3. Comparison of h-CD22 and m-CD22 structures
(A) BLAST alignment of the extracellular regions of murine CD22 and human CD22. Key amino acids are highlighted in
blue and Cys forming disulfide bridges in green. Sequence corresponding to the V-set domain is evidenced in pink,
sequence of C2-set domains in purple. Conservation between the two sequences is evaluated using Jalview (Waterhouse
et al., 2009).
(B) Comparison of the N-terminal V-set domains of h-CD22 (pink), PDB: 5VKM, and m-CD22 homology model (orange).
Common residues constituting the binding sites are highlighted in cyan. Residues of m-CD22 pocket differing from h-




Articledisplayed a similar binding mode inside the receptors pocket, in accordance with NMR data, showing the
involvement of the following major determinants of sialylated ligands binding, i.e. the conserved arginine
(Arg120h and Arg124m ) and aromatic residues (Trp24h, Trp128h and Trp26m, Trp132m) (Ereño-Orbea et al.,
2017). It is worth noting that with both h-CD22 and m-CD22, the ligand assumed an umbrella-like confor-
mation in the chosen clusters.
To finely describe the complexes between Neu5Gc-containing glycans and h- and m-CD22, the afore-
mentioned structures were used as starting point to run MD simulations throughout 100 ns. Along the
trajectory, the receptor, and ligand RMSD, the ligand dihedral angles fluctuations, as well as hydrogen
bonds and contacts between the ligand and the receptor were monitored (Figures S3–S5). In either com-
plexes, the ligand remained anchored to both h-CD22 and m-CD22 receptors until the end of the simu-
lation, as demonstrated by the ligand RMSD values within 1.5/2 Å, suggesting the stability of the bind-
ing poses (Figures S4A and S4C). Representative complexes selected on the basis of the cluster analysis
of the dynamics (see Methods section for details) were then analyzed by means of the CORCEMA-ST
program (Jayalakshmi and Krishna, 2002) that allowed the comparison between the theoretical and
the experimental STD data and the validation of 3D models of the complexes (Figures 3 and 4). Thus,6 iScience 24, 101998, January 22, 2021
Figure 4. Interaction between h-CD22 and Neu5Gc ligand
(A) Three-dimensional model of Neu5Gc ligand bound to h-CD22 V-set domain as derived by STD, tr-NOESY, and MD.
(B) The three-dimensional h-CD22/Neu5Gc complex showing the best fit between theoretical (solid line) and
experimental (dashed line) STD data derived by CORCEMA-ST analysis. (R-NOE values of 0.24).
(C) Two-dimensional plots representing the interactions between the glycolylated trisaccharide and h-CD22-binding site
residues, derived from a representative frame of the MD simulation. Dotted arrows represent hydrogen bonds with
functional groups from side chains and solid arrows those with functional groups of the backbone. The interaction




Articleas for the h-CD22/Neu5Gc model, several contacts between the ligand and the receptor binding pocket
residues were observed; the majority of them were retained for most of the simulation time (Figure S4B).
In particular, the polar network between h-CD22 and the glycolylated ligand was similar to that already
described for the corresponding Neu5Ac ligand. (Di Carluccio et al., 2019) Indeed, the highly conserved
Arg120 established a salt bridge between its guanidine group and Neu5Gc carboxylate. Neu5Gc glyc-
erol moiety was involved in hydrogen bonds with Met129 backbone oxygen and amide, as well as
CH-p contacts with Trp128. Also, the Neu5Gc OH-4 formed a polar interaction with Glu126. Most impor-
tantly, the N-glycolyl group of Neu5Gc engaged a stable hydrogen bond with Lys127 and hydrophobic
contacts between its methylene protons and both Trp24 and Trp128 aromatic moieties (present 82% and
100% of the simulation time, respectively, as shown in Figure S4B). The Gal unit contributed to the re-
ceptor binding by means of CH–p interaction with Tyr64 aromatic residue (present for 100% of the simu-
lation time). On the contrary, the GlcNAc unit was far from the h-CD22 surface for most part of the simu-
lation, and this sugar moiety displayed higher RMSD with respect to the other sugar units (Figure S5A).
Concerning the conformational behavior along the MD simulation, the bound ligand maintained the um-
brella topology for 82% of the simulation (Figure S5B). Indeed, the distance between the CH3 group of
the N-acetyl glucosamine and the H-5 of sialic acid assumed an average value of 4.9 Å, in accordance
with the NOE derived distance (Figure S5C and Table S3).
The CORCEMA-ST highlighted a good agreement between the theoretical and experimental values
(Figure 4B). Indeed, the strongest STD effects in the h-CD22 complex were predicted for protonsiScience 24, 101998, January 22, 2021 7
Figure 5. Interaction between m-CD22 and Neu5Gc ligand
(A) Three-dimensional model of Neu5Gc ligand bound to m-CD22 V-set domain as derived by STD, tr-NOESY, and MD.
(B) The three-dimensional m- CD22/Neu5Gc complex showing the best fit between theoretical (solid line) and
experimental (dashed line) STD data derived by CORCEMA-ST analysis. (R-NOE values of 0.21).
(C) Two-dimensional plots representing the interactions between the glycolylated trisaccharide and m-CD22 binding site
residues, derived from a representative frame of the MD simulation. Dotted arrows represent hydrogen bonds with
functional groups from side chains and solid arrows those with functional groups of the backbone. The interaction




Articlebelonging to Neu5Gc unit; significant saturation was also estimated for some protons of the Gal unit;
conversely no saturation was predicted for protons of GlcNAc units, in full agreement with the exper-
imental STD data (Figures 2B and S1A, Table S2). The high STD value of the glycolyl group of the
ligand was consistent with the close contacts with Trp24, Trp128, and Glu126 side chains. Regarding
STD data of the Neu5Gc glycerol moiety, the higher STD effect observed for the H-7 is due to the
strong CH-p interaction of this proton with Trp128 indole group, beyond the contacts between the
entire moiety and Met129. Concerning the hydroxymethylene group, only the H-9S was oriented to-
ward Trp128, thus exhibiting a higher STD effect with respect to H-9R. Also, H-4 and H-6 of Neu5Gc
displayed significant STD effects for their vicinity to the receptor surface. For the Gal unit, considerable
saturation was predicted especially for the proton at position 4, due to its close contacts with Tyr64
aromatic ring.
As for m-CD22/Neu5Gc-validated model, the ligand interaction pattern showed many similarities with its
human ortholog. Still, Neu5Gc majorly contributed to the binding, interacting with Arg124, Arg131,
Trp132, and Met133 receptor residues, whereas no participation of GlcNAc residue was observed (Figures
5 and S4D). Specifically, the carboxylate of Neu5Gc formed the key electrostatic interactions with the
Arg124 guanidinium group. Met133 established numerous polar interactions with the hydroxyl groups of
the ligand glycerol moiety. In addition, the Arg131 played the same role of Lys127 in h-CD22 receptor,
thus forming a stable hydrogen bond between its backbone oxygen and the amide nitrogen of Neu5Gc
N-glycolyl moiety, which was also in close contact with Trp26 and Trp132 aromatic residues (present for




ArticleDifferently from h-CD22 complex, the hydroxyl group of theN-glycolyl moiety forms polar interactions with
Asp25 and Asn24 residues, which lie in proximity of the binding region, although these contacts were
observed for 60% and 40% of the MD simulation, respectively. Furthermore, similarly to h-CD22 binding
mode, the Gal unit is mostly engaged in CH–p interaction with Phe-68 residue (contact present for 99%
of the simulation time); also, the GlcNAc residue did not interact with m-CD22, exhibiting a higher degree
of fluctuation with respect to the other residues (Figure S5D). In accordance with the experimental data, the
ligand retained an umbrella-like conformation for 89% of the simulation time, as supported by the average
distance between the CH3 group of theN-acetyl glucosamine and the H-5 of Neu5Gc along the simulation
(Figures S5E and S5F).
Thus, a comparison of CORCEMA-ST results of m-CD22 and h-CD22 in complex with Neu5Gc-containing
trisaccharide highlights how the orientation of the glycan inside the receptors binding pockets is compa-
rable. The strong STD value observed for N-glycolyl moiety of Neu5Gc in the interaction with m-CD22
could be explained by the contacts between the hydroxymethyl group and Asp25 and Asn24 residues,
beyond those observed with the Trp26 and Trp132 aromatic residues and the hydrogen bond with
Arg131, analogous to that described in the human receptor. The potential involvement of the Asp25 in
the recognition ofN-glycolyl trisaccharide by m-CD22 was supported by the results of CORCEMA-ST anal-
ysis performed on several other structures lacking the hydrogen bond with the Asp25, resulting in higher R-
NOE values due to the significantly lower STD value attributed to the N-glycolyl moiety protons (data not
shown). Considering the Gal moiety, similar STD effects were predicted for the protons directed toward the
residue aromatic side chain, namely H-4 and H-3, in line with conservative mutation of Tyr64h into Phe68m.STD NMR analysis revealed a comparable recognition profile of the acetylated 6’SLN by
murine and human CD22
The STD NMR analysis of the interaction of Neu5Ac-containing trisaccharide [Neu5Ac-a-(2,6)-Gal-b-(1,4)-
GlcNAc] with murine CD22 (Figures 2C and S1A, left panel) revealed an epitope map and a binding
mode fully comparable to that of human CD22, previously characterized by our group (Di Carluccio et
al., 2019). The several changes in the multiplicity and relative intensity of signals observed in the STD
NMR spectrum with respect to the corresponding reference (Figure S1A) were diagnostic of the binding
specificity. In detail, the sialic acid residue (K) mostly participated to the interaction with m-CD22, with
the acetyl group giving the highest STD signal. On the contrary, the acetyl group belonging to the glucos-
amine residue (A) disappeared from the STD spectrum, highlighting its distance from the binding site. In
addition, H-6 proton of sialic acid gave a good STD signal, close to 70%, followed by the protons belonging
to the glycerol chain and the H5 (range of 30%–50%). The contribution of the diastereotopic H-3 protons
was less remarkable (<30%). Interaction of the galactose unit (B) was also detected, mainly relative to pro-
tons H-4, H-5, and H-6. Notably, as further confirmation of the binding specificity, the multiplet around 3.9
ppm in the off-resonance, deriving from the overlapping of H-6 A and H-6 B, was converted into a triplet
corresponding to the only H-6 Gal B in the STD spectrum, further evidence that the N-acetylglucosamine
moiety was excluded from the recognition process. Additional data gathered from the construction of STD
build-up curves (Figure 2C) corroborated the results obtained from the qualitative STDNMR analysis (Table
S5). The above experimental data highlighted a totally comparable binding mode of Neu5Ac-containing
trisaccharide with human and murine CD22.Comparison of acetylated and glycolylated glycans interaction with murine and human CD22
To directly compare the mode of interaction of Neu5Ac/Neu5Gc with m-CD22, a computational approach
was performed to establish a three-dimensional complex of m-CD22 and Neu5Ac glycans, thus defining a
reliable model of interaction (Figure 6). According to our results, the Neu5Ac ligand displayed a similar
orientation with respect to Neu5Gc ligand, establishing the crucial salt bridge with Arg124 through its
carboxylate. The hydroxyl groups of the glycerol lateral chain interacted through hydrogen bonds with
the Met133 backbone. The N-acetyl group was involved in the binding with Arg131 as well as hydrophobic
interactions with Trp26 and Trp132 aromatic residues. The Gal residue, similarly to Neu5Gc ligand, was
involved in CH-p interactions with Phe68, and the GlcNAc was far from the binding region. Thus, it can
be assessed that m-CD22 interacts with Neu5Ac and Neu5Gc ligands in analogous manner. A comparison
of the 3D structures of the models showed slightly different shape and polarity of the receptor cavities,
which accommodate the Neu5Ac and Neu5Gc moieties (Figures 6A and 6B). Indeed, although the h-
CD22 region responsible for N-acetyl and N-glycolyl binding is essentially constituted by aromaticiScience 24, 101998, January 22, 2021 9
Figure 6. Comparison of the interaction of Neu5Ac/Neu5Gc ligands with m-CD22 and h-CD22
(A) Close up view ofN-Acetyl (purple)- andN-glycolyl (cyan)-binding region of h-CD22, showing the protein surface (pink).
(B) Close up view of N-Acetyl (purple)- and N-glycolyl (cyan)-binding region of m-CD22, showing the protein surface
(orange).
(C) Superimposition of h-CD22/Neu5Gc (pink) and h-CD22/Neu5Ac complexes (dirty violet).




Articleresidues, m-CD22 also comprises the Asp25 residue in optimal position to interact with the longer N-gly-
colyl chain.
Finally, MM/GBSA and MM/PBSA analysis (Srinivasan et al., 1998) was performed with Amber to have an
indication of the relative binding energy of the complexes (Table 1). As result, all four complexes exhibited
comparable DGb values, in agreement with the similar binding properties of the receptors toward the
different forms of sialic acid discussed here (Figures 6C and 6D). Therefore, despite some differences in
the binding regions described earlier, it is possible to assess that human and murine CD22 similarly recog-
nize Neu5Ac and Neu5Gc ligands, in accordance with the experimental results.DISCUSSION
The family of Sias includes nearly 50 structurally diverse members deriving from naturally occurring mod-
ifications in different positions of the original nonulosonic acid skeleton (Pearce and Läubli, 2016). Usually,
Sias cap the terminal moiety of cell surfaces glycoconjugates and glycolipids as well as secreted glycopro-
teins are attached to the underlying glycan via a-(2/3), a-(2/6), or a-(2/8) linkages. By virtue of their
location, diversity, and ubiquity in vertebrates, Sias serve as ligands of endogenous and exogenous
glycan-binding proteins, thus representing important regulators of several biologically relevant recogni-
tion processes (Varki, 2008). Sialylated glycans from human cells mainly terminate with the 50-acetylated iso-
form of neuraminic acid, Neu5Ac, because of the evolutionary loss of the Neu5Gc, which differs from
Neu5Ac by one additional oxygen atom. In contrast with the majority of other mammals, humans do not
possess the ability to synthesize Neu5Gc; it can, however, be metabolically incorporated from dietary sour-
ces, i.e. red meat, and becomes present on some epithelial and endothelial cell surfaces (Alisson-Silva
et al., 2018). Also, the presence of Neu5Gc on nontypeable Haemophilus influenzae (NTHi) LOS (lipooligo-
saccharide) that forages exogenous sialic acids from the host was recently demonstrated (Ng Preston,
2018). Being Neu5Gc a xeno-autoantigenmostly present on malignant cells, the interaction between inhib-
itory CD22 andNeu5Gc glycansmay indeed play a key role in the regulation of the tumor immune response
(Samraj et al., 2014), impact on cancer progression, and increase of tumor-associated inflammation. Here,
we evaluated the effect of sialic acid glycolylation on the binding with CD22, comparing the behavior of
different ligands in complex with murine and human CD22, improving the knowledge of the structural basis
of the recognition of sialylated N-glycans from CD22 receptor.10 iScience 24, 101998, January 22, 2021
Table 1. Relative binding energies of h-CD22 and m-CD22 with acetylated and glycolylated ligands
Complex DGb (MM/GBSA) DGb (MM/PBSA)
h-CD22/Neu5Gc 41.24 G 0.15 12.66 G 0.16
h-CD22/Neu5Ac 38.43 G 0.18 10.75 G 0.18
m-CD22/Neu5Gc 38.29 G 0.16 11.73 G 0.19
m-CD22/Neu5Ac 34.69 G 0.26 10.72 G 0.18




ArticleNMR analysis revealed a comparable binding epitope of both murine and human CD22 toward glycoly-
lated glycans (Figures 2A–2C and S1). In both complexes a bent umbrella-like conformation of the ligand
was adopted, as supported by the results achieved from the NMR data and MD simulations (Figures S1B,
S1C, S5C, and S5F). From molecular modeling, it was confirmed that Neu5Gc/Neu5Ac ligands displayed a
similar orientation inside the binding site of murine and human CD22, independently from the Sia nature,
as supported by a comparison of the molecular surfaces of h-CD22 and m-CD22 in the interaction with N-
acetyl/N-glycolyl Sia chains, in Figure 6. Furthermore, it was evidenced the possibility for m-CD22 of form-
ing additional interactions with Neu5Gc ligand, mainly involving the hydroxymethyl group of N-glycolyl
moiety. This was further supported by a comparison of the molecular surfaces of h-CD22 and m-CD22
deputed to interact with N-acetyl/N-glycolyl Sia chains. In addition, the substitution of Asp25m in place
of Lys23h in the binding subsite of m-CD22 influences the possibility to establish hydrogen bonds with
the hydroxyl group of the glycolyl moiety.
Overall, our studies indicate that, despite the different nature of sialic acid residue, the recognition region
of h-CD22 is almost invariant comparing Neu5Ac and Neu5Gc containing glycans. These results agree with
the similar affinity of h-CD22 toward Neu5Gc/Neu5Ac structures, as recently reported by Angata (Angata,
2018). In conclusion, the obtained outcomes provide a global vision of how the most diffuse neuraminic
acid forms of sialylated N-glycans in mammals are arranged in the binding pocket of CD22. Hence, poten-
tial high-affinity analogues of ligands naturally recognized from the CD22 could be specifically designed
and synthetized for targeting the receptor protein in order to impede the biological interaction, thus
modulating immune responses.Limitations of the study
This study reports the interactions of the biologically relevant CD22, in human andmurine variants, with the
two predominant forms of sialic acid in vertebrates. A comparison of the binding mode was carried out
mainly by NMR spectroscopy, molecular modeling, and CORCEMA-ST calculations. In the absence of
high-resolution coordinates of the murine CD22, we employed homology modeling and different compu-
tational approaches to validate the generated models (docking, MD simulations, CORCEMA-ST). Despite
the high homology with respect to the template, the structural conclusions we derived from homology
modeling will require the definition of the three-dimensional structure of the murine CD22 to avoid misin-




This study did not generate new unique reagents.
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Figure S1. [Comparison of the binding mode of Neu5Ac/Gc containing ligands when interacting with 
h-/m- CD22], related to Figure 2 and Table S3. a) Left panel: STD-NMR of Neu5Ac ligand interacting with 
m/h-CD22. Right panel: STD-NMR of Neu5Gc ligand interacting with m/h-CD22. STD NMR analyses were 
performed using a protein/ligand molecular ratio of a 1:100 and saturation time of 2s. Neu5Ac/Gc ligands 3D 
epitope maps are also shown. b) Tr-NOESY NMR spectrum of the glycolylated trisaccharide in the bound state 
with h-CD22, using a mixing time of 400ms. c) Tr-NOESY NMR of the glycolylated trisaccharide bound to m-
CD22, using a mixing time of 400ms. The ligand 6’SLN upon binding with both h- and m-CD22 adopts an 
umbrella-like topology, depending on the parameter θ, defined as the angle between the carbon C-2 of Sia 
and C-1 atoms of the Gal and GlcNAc residues, that assumes a value < 110°. The experimental error in the 
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Figure S2. [MD simulation analysis of the glycolylated trisaccharide in its free state], related to Figure 
2 and Table S3 
a) φ/ψ/ω dihedral angles of Neu5Gc-Gal linkage along the MD trajectory. 
b) φ/ψ/ dihedral angles of Gal-GlcNAc linkage along the MD trajectory. 
c) H3eq Neu5Gc – H6S/H6R Gal inter-ligand distances. 
d) H3ax Neu5Gc – H6S/H6R Gal inter-ligand distances. 
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Figure S3. [MD simulation analysis of m-CD22 homology modelling], related to Figure 3.  
a) Superimposition of the m-CD22 structures each 10 ns of the MD simulations. Along the MD simulation, 
no relevant conformational changes emerged. 
b) Backbone RMSD of the protein, CC’ loop (res 69-74), GG’ loop (res 127-130), depicted in black, red 
and green respectively. The fluctuations of the backbone RMSD of the CC’ loop, can be attributed to 
a dynamic equilibrium between a disordered (high RMSD) and partially ordered (low RMSD) forms of 
the region. 
c) Atomic fluctuation by residue of m-CD22 structure, calculated using the protein C atoms. The peaks 
in the RMSF plot corresponded to the mobile loops connecting the ß-strands, in both V-set and C2-
set Ig-like domains. 
d) Plot of the potential energy variation of m-CD22 structure along the MD. The structure with the lowest 
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Figure S4. [MD simulation analysis of h-CD22/m-CD22 complexes with the glycolylated ligand], related 
to Figures 4 and 5. 
a) h-CD22 and Neu5Gc ligand RMSD variation along the MD. The ligand RMSD was measured with 
respect to the protein. 
b) Frequency of most representative h-CD22/Neu5Gc inter-molecular distances. A distance cut-off of 
5Å was considered for the calculation.  
c) m-CD22 and Neu5Gc RMSD variation along the MD. A distance cutoff of 5Å was considered for the 
calculation. 












Figure S5. [Analyses of the glycolylated ligand conformation when bound to h-CD22 and m-CD22], 
related to Figures 4 and 5. 
a) RMSD of Neu5Gc ligand residues with respect to h-CD22 protein. 
b) Distance between H5 of Neu5Gc and GlcNAc acetyl group C (CME) (average value 5.1 Å). 
c) Variation of Neu5Gc  angle value along h-CD22/Neu5Gc complex simulation. The parameter θ is 
defined as the angle between the carbon C-2 of Sia and C-1 atoms of the Gal and GlcNAc residues. 
d) RMSD of Neu5Gc ligand residues with respect to the m-CD22 protein. 
e) Distance between H5 of Neu5Gc and GlcNAc acetyl group C (CME) (average value 4.9 Å). 
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Figure S6. [Interaction between m-CD22 and Neu5Ac ligand], related to Figure 6 
a) Protein and ligand RMSD variation along the MD. The ligand RMSD was measured with respect to 
the protein. 
b) Distance between H5 of Neu5Gc and GlcNAc acetyl group C (CME) (average value 4.6 Å) 
c) Three-dimensional model derived by STD, tr-NOESY and MD for the Neu5Ac ligand bound form (gt 
conformer) to m-CD22 homology model. The representative frame from the most populated MD 
cluster was considered to depict the complex. 
d) Two-dimensional plots representing the interactions between the glycolylated trisaccharide and the 
binding site residues of m-CD22. The representative frame of the most populated MD cluster was 
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Table S1. [Experimental STD intensities of glycolylated 6’SLN bound to m-CD22], related to Figure 2a. 
STDmax values were evaluated by fitting the data to a monoexponential equation: 𝑆𝑇𝐷 = 𝑆𝑇𝐷𝑚𝑎𝑥(1 − 𝑒−𝑘𝑠𝑎𝑡𝑡𝑠𝑎𝑡) 




 STD (fit) % STD epitopes (fit) 
CH2 Neu5Gc 9.4963 0.8017 7.6132 100 
H7 Neu5Gc 6.9388 0.6038 4.1897 55.0 
H4 Gal 6.1757 0.6239 3.8530 50.6 
H5 Gal 5.7199 0.6108 3.4937 45.9 
H9S Neu5Gc 4.1764 0.7117 2.9723 39.0 
H6R Gal 3.5266 0.7722 2.7232 35.8 
 




 STD (fit) % STD epitopes (fit) 
CH2 Neu5Gc 8.3838 0.6205 5.2021 100 
H7 Neu5Gc 6.6503 0.5120 3.4049 65.4 
H4 Gal 5.4644 0.4935 2.6967 51.8 
H9S Neu5Gc 3.8238 0.6113 2.3375 44.9 
H6R Gal 3.0547 0.7042 2.1511 41.3 
 
Table S3. [Theoretical and experimental 1H-1H inter-proton distances of the glycolylated trisaccharide 
in the free and bound states with human and murine CD22], related to Figures 21b,c.  Estimated error 
5–10%. 
Distances Family I 
Φ = -60° 
Ψ = 180  
ω  = 60° 
Family II 
Φ = 180  
Ψ = 180  














H3eq Neu5Gc - H6S Gal 4.93 3.84 4.50 4.61 4.72 
H3eq Neu5Gc - H6R Gal 4.58 3.37 nd nd nd 
H3ax Neu5Gc - H6S Gal 4.43 2.53 4.11 4.80 4.90 
H3ax Neu5Gc - H6R Gal 4.25 2.35 nd nd nd 
H5 Neu5Gc - CH3 GlcNAc 4.30 9.60 nd 4.96 4.81 
 
Table S4. [Cluster rank, Cluster population, computed binding energy and RMSD (Root Mean Square 
Deviation) for the molecular docking (AutoDock) of m-CD22/ligand and h-CD22/ligand complexes], 
related to Figures 4 and 5 










h-CD22 1 154 -2.57 2.37 
m-CD22 3 85 -1.94 3.23 
 





 STD (fit) % STD epitopes 
(fit) 
CH3 Neu5Ac 5.7320 0.4884 2.7995 100 
H6 Neu5Ac 3.7105 0.5080 1.8849 67.3 
H4 Gal 2.9244 0.5187 1.5169 54.2 
H5 Gal 2.1719 0.5580 1.2119 43.3 
H6R Gal 1.5247 0.6170 0.9407 33.6 
H5 Neu5Ac 1.6331 0.5256 0.8584 30.6 





Protein expression and purification. The plasmids encoding for the three N‐terminal Ig‐like domains of human 
CD22 and murine CD22, respectively fused to the Fc region of mouse IgG2b and human IgG1, were expressed 
in CHO cell lines and purified as described elsewhere (Di Carluccio, et al., 2019).
Fluorescence titration. Steady-state fluorescence spectra have been collected on a Fluoromax-4 
spectrofluorometer (Horiba, Edison,NJ, USA) at the fixed temperature of 10°C. Emission spectra were 
recorded in the emission range of 300–500 nm upon excitation at 285 nm. The slit widths were fixed at 4 nm 
for the excitation and 10 nm for the emission wavelength. A quartz cuvette with a path length of 1 cm and 0,2 
mL volume was used. m-CD22 and h-CD22 solutions at fixed concentration of 0.25 μM in PBS buffer (pH 7.4) 
were titrated by adding small aliquots of a ligand stock solution of 100 μM) of Neu5Ac and Neu5Gc ligands. 
The fluorescence of both proteins found to quench in the presence of the ligands. The binding curve was 
obtained by plotting F/Fmax values versus ligand concentration and fitting the data through non-linear 











a=[F]tKb , b=1+[Y]tKb, c=[Y]tKb  where [F]t and [Y]t represent the total concentration of protein and ligand, 
respectively. 
 
NMR analysis. Samples were prepared using 50mM phosphate deuterated buffer, pH 7.4. All NMR 
experiments were recorded on a Bruker AVANCE NEO 600-MHz equipped with a cryo probe and the analyses 
were performed with TOPSPIN 3.2 software.  
Tr-NOESY analysis. Homonuclear 2D 1H-1H ROESY and 1H-1H NOESY experiments were carried out at 298°K 
by using data sets of 4096x256 points and mixing times of 600 ms for the free state and 400 ms for the bound 
states. Proton – proton cross relaxation rates (σij) were measured integrating the ROE/NOE cross peaks of 
interest normalizing against the corresponding cross peak on the diagonal in F1. The experimental distances 
(rij) were calculated by employing the isolated spin pair approximation using as reference the intra-residue 
distance H1-H5 of the N-acetylglucosamine residue as 2.6Å.  
STD NMR analysis. STD NMR experiments were acquired with 32 k data points and zero-filled up to 64 k data 
points prior to processing. 40 Gauss pulses with a length of 50 ms were used to selectively irradiate the protein 
resonances, setting the on-resonance pulse at 7.5 ppm and the off-resonance pulse frequency at 40 ppm. To 
suppress the water signals, an excitation sculpting with gradient pulses (esgp) was applied. A protein/ligand 
molar ratio of 1:100 was used for all systems. The fractional STD effects were calculated by use of (I0 – Isat)/I0, 
with Isat the intensity of the signal in the STD NMR spectrum and I0 the peak intensity of an unsaturated 
reference spectrum (off-resonance). The STD curves were acquired at different saturation times, from 0.8 to 
5s. The STD build up curves were performed by fitting the saturation time data to a monoexponential equation 
of the form: 𝑆𝑇𝐷 = 𝑆𝑇𝐷𝑚𝑎𝑥(1 − 𝑒−𝑘𝑠𝑎𝑡𝑡𝑠𝑎𝑡), where STD stands for the STD signal intensity corresponding to the 
saturation transfer of a given proton at a saturation time tsat, STDmax represents the asymptotic maximum of 
the curve, and ksat is the observed saturation rate constant that measures the speed of STD build-up. The 
value of STDfit was derived by the slope of the STD build-up curve at a saturation time of 0. Once calculated 
both STDfit and Ksat values, all the intensities of different protons ligand were normalized to the largest STDfit, 
giving STDepitopes fit.  
 
Homology modeling.  The sequence encoding for m-CD22 (Uniprot: NP_033975.3) was obtained from NCBI 
(http://www.ncbi.nlm.nih.gov). For computational 3D structure calculation by homology modeling, the 
extracellular V-set, and C2 set domains of murine CD22 were considered. The sequence interval 
corresponding to the extracellular portion was aligned to hCD22 template (PDB: 5VKJ), using BLAST (Altschul 
et al., 1990) homology model was generated by means of SWISS-MODEL (Waterhouse et al., 2018). Then, 
the obtained structure was subjected to 100ns molecular dynamics (MD) simulations for geometry optimization 
and to evaluate the stability of the model.  
 
 
Molecular dynamics simulations. To run the MD simulation of h-CD22 and m-CD22, only the corresponding V-
set domain and adjacent C2-set domain were considered (19-355). Missing residues in h-CD22 CC’ loop were 
added with the help of ModLoop (Fiser et al., 2000), prior to MD simulation, the structure was then refined; 
for each system missing hydrogen atoms were added, and protonation state of ionisable groups was computed 
using Maestro Protein Preparation Wizard (Schrodinger, 2012). MD simulations were carried out using AMBER 
18 suite of programs (Case et al., 2018) to investigate the ligands behavior in solution, to assess the stability 
of the homology models, the mobility of the loops and the stability of the docking poses. Atom types and 
charges were assigned according to AMBER ff14SB force field for the proteins and GLYCAM-06j-1 force field 
to represent the ligands. By using the Leap module, the proteins and ligands were hydrated with octahedral 
boxes containing explicit TIP3P water molecules buffered at 10 Å, also, Na+ counter ions were added to 
neutralize the system by using the Leap module. The systems minimization was performed using Sander and 
MD simulations were carried out using the CUDA, which are distributed within the AMBER 18 package.  
The smooth particle mesh Ewald method was used to represent the long-range electrostatic interactions in the 
system while each simulation was under periodic boundary conditions, and the grid spacing was set to 1 Å. In 
the equilibration procedure, the system was minimized by applying a restriction to the protein which was 
gradually released in the following steps. Then slow system thermalization from 0°K to 300 °K was carried out 
applying a solute restraint. Temperature was increased from 0°K to 100°K at constant volume. Then, from 
100°K to 300°K in an isobaric ensemble. Thereafter, temperature was kept constant at 300 °K during 50 ps 
with progressive energy minimizations and solute restraint. Once completed the restraints were removed and 
the systems then advanced in an isothermal-isobaric ensemble along the production.  
Concerning the complex MD simulation, an harmonic restraint to the ligand ω dihedral angle between Neu5Gc 
and Gal unit was applied to keep its value to keep its value around 60 degrees. considering the gt bioactive 
conformation derived from NOE experimental data. 
Coordinates were archived in order to acquire 10000 structures of the progression of the dynamics.  
Trajectories were analyzed with the ptraj module included in the AMBER18 and visualized with VMD molecular 
visualization program. Each trajectory was submitted to cluster analysis with respect to the ligand RMSD using 
K-mean algorithm implemented in ptraj module. The representative structure of the most populated cluster 
was considered to depict the complexes interactions. 
 
Ligand-protein docking calculations. Preparation of the macromolecules. The crystal structure of h-CD22 and 
m-CD22 refined 3D coordinates were used for docking purposes. Each structure was then submitted to 100000 
steps of steepest descent minimization with OPLS3 force field using MacroModel (Schrödinger Release 2020-
2, 2020) before being used for docking calculations.  
Building of ligands. The 3D coordinates of Neu5Gc-α-(2-6)-Gal-β-(1-4)-GlcNAc and Neu5Ac-α-(2-6)-Gal -β-(1-
4)-GlcNAc were built by means of Glycam (Woods Group, 2005-2020).The ligands geometries were optimized 
by 100000 step of steepest descent minimization with OPLS3 force field using Macro Model. Ligands were 
prepared for docking calculations using AutoDockTools, setting all rotatable bonds free to move during the 
docking calculations. An MD simulation, to investigate the conformational behavior of Neu5Gc-α-(2-6)-Gal-β-
(1-4)-GlcNAc was also performed. 
Docking calculations. Docking calculations of all compounds were performed using AutoDock 4.2.2 (Morris et 
al., 2009). Analysis of the docking poses was performed with AutoDockTools. The docking protocol was 
validated by carrying out the docking of CD22 crystallographic structure in complex with Neu5Ac-α-(2-6)-Gal 
ligand (PDB: 5VKM). The 3D structure of Sia-α-(2-6)-Gal was extracted from the crystallographic structure of 
CD22.The grid point spacing was set at 0.375 Ǻ, and a hexahedral box was built with x, y, z dimensions: 64 
Ǻ, 46 Ǻ, 56 Ǻ centered in the centroid position among the binding site residues. A total of 200 runs using 
Lamarckian Genetic algorithm was performed, with a population size of 100, and 250000 energy evaluations. 
Based on energy and cluster populations, promising h-CD22/ and m-CD22/Iigand complexes were identified 
and further subjected to MD simulations. 
 
CORCEMA-ST. CORCEMA-ST protocol was used as previously described (Jayalakshmi and Krishna, 2000). 
The pdb coordinates of complexes were selected from the MD trajectory analyses. The conformation of the 
ligand was assumed to be invariant in free and bound state. The input variables, as the concentration of the 
ligand and the protein, were experimentally derived. The saturation time was set to 2s and the dissociation 
constants (KD) were set on the basis on the experimentally derived for h-CD22/ Neu5Ac-α-(2-6)-Gal-β-(1-4)-
GlcNAc complex23 and further adjusted to get the best fit. A binding site cutoff of 8 Å was employed. By 
computing the R matrix and the calculation of spectral densities, the fractional intensity changes were 
calculated for each ligand protons and compared to the experimental STD effects by means of a NOE R factor, 
a normalized root-means square deviation value. For the calculations, only the STD values of the ligands 
isolated signals were considered.  Figures of the selected complexes were done using Pymol 2.4.0 
(Schrödinger, LLC, 2000). 
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